Antisense peptides

Sun L., Fuselier J.A., Murphy W.A., Coy D.H. Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxity to human neuroblastoma 1M.R.32 cells expressing somatostatin receptors. Peptides 2002 23 1557-1565. 

Rapozzi V., Burm B.E.A., CoGOi S., Van DER Marel G.A., Van Boom J.H., Quad-RiFOGLio F., XoDO L. E. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res. 2002 30 3712-3721. 

Filipovska A, Eccles MR, Smith RAJ, Murphy MP. Delivery of antisense peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a lipophilic cation. FEES Lett 2004 556 180-186. 

Fassina G, Zamai M, Brigham-Burke M et al. Recognition properties of antisense peptide to Arg-8-vasopressin/bovine neurophysin II biosynthetic precursor sequences. Biochemistry 1989 28 8811. 

Generally refers to a nucleotide sequence that is complementary to a sequence of messenger RNA, which is the product of the noncoding sequence of DNA. It also refers to the peptide products from the antisense sequence referred to as antisense peptides. Antisense peptides have been investigated for biological activity. siRNA are based on the processing of antisense RNA. See Korneev, S. and O Shea, M., Natural antisense RNAs in the nervous system, Rev. Neurosci. 16, 213-222, 2005. See also MicroRNA, siRNA, Antisense Peptides, Aptamers. 

The products from the translation of antisense RNA. Some antisense peptides have been demonstrated to show affinity properties that appear to be unique to that sequence and not seen in scrambled sequences. See Schwabe, C., New thoughts on the evolution of hormone-receptor systems, Comp. Biochem. Physiol. A 97, 101-106, 1990 Chaiken, I., Interactions and uses of anti-sense peptides in affinity technology, J. Chromatog. 597, 29-36, 1992 Labrou, N. and Clonis, Y.D., The affinity technology in downstream processing, J. Biotechnol. 36, 95-119, 1994 Root-Bernstein, R.S. and Holsworth, D.D., Antisense peptides critical mini-review, J. Theoret. Biol. 190, 107-119, 1998 Siemion, I.Z., Cebrat, M., and Kluczyk, A., The problem of amino acid complementarity and antisense peptides, Curr. Protein Pept. Sci. 5, 507-527, 2004. 

Joergensen, M., Agerholm-Larsen, B., Nielsen, P.E., and Gehl, J. (2011) Efficiency of cellular delivery of antisense peptide nucleic acid by electroporation depends on charge and electroporation geometry. Oligonucleotides, 21, 29-37. 

Figure 7.41 Complementary peptide derivation (a) Three ribbon structure views of interleukin-1/3 (IL-1/3) X-ray structure (pdb lilb), showing (top side) key receptor binding residue regions (yellow) and the Boiaschi loop (red). Overlay structure involves superposition of Interleukin-1 receptor antagonist (IL-lra) X-ray structure (pdb lilt) upon IL-1 8 (side view) to demonstrate the general structural similarity between these protein family member proteins, but also the absence of Boraschi loop in IL-lra. IL-lra is the only known natural inhibitor of IL-1 8. (b) mRNA sequence of Boraschi loop and decoded amino acid residue sequence (red) set alongside deduced mRNA sequence of complementary peptide and decoded amino acid residue sequence (blue), (c) Structure of complementary peptide corresponding with the Boraschi loop a potential complementary (antisense) peptide mini-receptor inhibitor of IL-1/3.

J. R. Heal, S. Bino, G. W. Roberts, J. G. Raynes and A. D. Miller, Mechanistic investigation into complementary (antisense) peptide mini-receptor inhibitors of cytokine interleukin-1, ChemBioChem, 2002, 3, 76-85. 

Roberto P. Stock, Alejandro Olvera, Ricardo Sanchez, Andreas Saralegui, Sonia Scarfi, Rosana Sanchez-Lopez, Marco A. Ramos, Lidia C. Boffa, Umberto Benatd, Alejandro Alagon, Inhibition of gene expression in Entamoeba histolytica with antisense peptide nucleic acid oligomers. Nature Biotechnology, 19 (2001), 231-234. 

Loo, J.A., Holsworth, D.D., and Root-Bernstein, R.S. (1994) Use of electrospray ionization mass spectrometry to probe antisense peptide interactions. Biol. Mass Spectrom., 23, 6-12. 

A newer, highly experimental approach to anxiety therapy is the use of antisense oligonucleotides to the anxiogenic peptide, NPY (44). 

Nielsen P.E., Egholm M., Berg R. H., Buchardt O. Peptide nucleic acids (PNA) oligonucleotide analogs with a polyamide backbone. In Antisense Research and Applications. Crooke S.T., Le-BLBu B. (Eds). CRC Press, Boca Raton,... 

HanveyJ.C., Peeeer N.J., Bisi J.E., Thomson S.A., Cadilla R., Josey J.A., Ricca D.J., Hassman C.F., Bonham M.A. Antisense and antigene properties of peptide nucleic acids. Science 1992 258 1481-1485. 

Mery J., Brugidou Rabie A. A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellu-lar oxytocin neurons. Nucleic Acids Res. 

Good L., Awasthi S.K., Dryselius R., Larsson O., Nielsen P.E. Bactericidal antisense effects of peptide-PNA conjugates. Nature Biotechnol. 2001 19 360-364. 

Koppelhus U., Nielsen P.E. Antisense properties of peptide nucleic acid (PNA). 

Koppelhus U., Awasthi S.K., Zachar V., Holst H.U., Ebbesen P., Nielsen P. E. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-pep-tide conjugates. Antisense Nucleic Acid Drug Dev. 2002 12 51-63. 

McMahon B.M., Mays D., Lipsky J., Stewart J.A., Fauq A., Richelson E. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 2002 12 65-70... 

Huang Y., Development of Antisense Alpha-Helical Peptide Nucleic Acids. PhD thesis. Case Western Reserve Unvierisity, Qeveland, OH, May 2002. 

---